IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
IDEXX Laboratories cash
Cash and short-term investments held at the end of each period.
IDEXX Laboratories's cash was $196.93M at Jun 30, 2026. For fiscal 2025 it was $180.07M, down 37.5% from the year before. Over ten years it grew -6.2% a year on average. The highest annual figure on record is $471.93M in fiscal 2017.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $180.07M | -37.5% |
| FY2024 | Dec 31, 2024 | $288.27M | -36.5% |
| FY2023 | Dec 31, 2023 | $453.93M | +303.3% |
| FY2022 | Dec 31, 2022 | $112.55M | -22.1% |
| FY2021 | Dec 31, 2021 | $144.45M | -62.4% |
| FY2020 | Dec 31, 2020 | $383.93M | +325.0% |
| FY2019 | Dec 31, 2019 | $90.33M | -27.0% |
| FY2018 | Dec 31, 2018 | $123.79M | -73.8% |
| FY2017 | Dec 31, 2017 | $471.93M | +20.4% |
| FY2016 | Dec 31, 2016 | $391.85M | +14.4% |
| FY2015 | Dec 31, 2015 | $342.59M | +6.2% |
| FY2014 | Dec 31, 2014 | $322.54M | +15.6% |
| FY2013 | Dec 31, 2013 | $279.06M | +24.6% |
| FY2012 | Dec 31, 2012 | $223.99M | +21.8% |
| FY2011 | Dec 31, 2011 | $183.90M | +17.2% |
| FY2010 | Dec 31, 2010 | $156.92M | +47.0% |
| FY2009 | Dec 31, 2009 | $106.73M | +35.3% |
| FY2008 | Dec 31, 2008 | $78.87M | +30.7% |
| FY2007 | Dec 31, 2007 | $60.36M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $196.93M | +19.6% |
| Q1 FY2026 | Mar 31, 2026 | $200.53M | +22.3% |
| Q4 FY2025 | Dec 31, 2025 | $180.07M | -37.5% |
| Q3 FY2025 | Sep 30, 2025 | $208.17M | -32.6% |
| Q2 FY2025 | Jun 30, 2025 | $164.59M | -59.0% |
| Q1 FY2025 | Mar 31, 2025 | $163.97M | -58.7% |
| Q4 FY2024 | Dec 31, 2024 | $288.27M | -36.5% |
| Q3 FY2024 | Sep 30, 2024 | $308.64M | -7.0% |
| Q2 FY2024 | Jun 30, 2024 | $401.59M | +202.3% |
| Q1 FY2024 | Mar 31, 2024 | $397.43M | +256.9% |
| Q4 FY2023 | Dec 31, 2023 | $453.93M | +303.3% |
| Q3 FY2023 | Sep 30, 2023 | $331.70M | +234.5% |
| Q2 FY2023 | Jun 30, 2023 | $132.84M | +16.2% |
| Q1 FY2023 | Mar 31, 2023 | $111.37M | -45.6% |
| Q4 FY2022 | Dec 31, 2022 | $112.55M | -22.1% |
| Q3 FY2022 | Sep 30, 2022 | $99.18M | -31.7% |
| Q2 FY2022 | Jun 30, 2022 | $114.36M | -50.7% |
| Q1 FY2022 | Mar 31, 2022 | $204.62M | -41.7% |
| Q4 FY2021 | Dec 31, 2021 | $144.45M | -62.4% |
| Q3 FY2021 | Sep 30, 2021 | $145.20M | -17.3% |
| Q2 FY2021 | Jun 30, 2021 | $232.13M | +120.5% |
| Q1 FY2021 | Mar 31, 2021 | $351.16M | +331.4% |
| Q4 FY2020 | Dec 31, 2020 | $383.93M | +325.0% |
| Q3 FY2020 | Sep 30, 2020 | $175.59M | +68.8% |
| Q2 FY2020 | Jun 30, 2020 | $105.29M | -5.0% |
| Q1 FY2020 | Mar 31, 2020 | $81.40M | -30.2% |
| Q4 FY2019 | Dec 31, 2019 | $90.33M | -27.0% |
| Q3 FY2019 | Sep 30, 2019 | $104.00M | -29.2% |
| Q2 FY2019 | Jun 30, 2019 | $110.85M | -36.5% |
| Q1 FY2019 | Mar 31, 2019 | $116.62M | -26.8% |
| Q4 FY2018 | Dec 31, 2018 | $123.79M | -73.8% |
| Q3 FY2018 | Sep 30, 2018 | $146.88M | -67.7% |
| Q2 FY2018 | Jun 30, 2018 | $174.56M | -58.7% |
| Q1 FY2018 | Mar 31, 2018 | $159.23M | -60.2% |
| Q4 FY2017 | Dec 31, 2017 | $471.93M | +20.4% |
| Q3 FY2017 | Sep 30, 2017 | $454.10M | +16.0% |
| Q2 FY2017 | Jun 30, 2017 | $422.90M | – |
| Q1 FY2017 | Mar 31, 2017 | $400.34M | – |
| Q4 FY2016 | Dec 31, 2016 | $391.85M | – |
| Q3 FY2016 | Sep 30, 2016 | $391.47M | – |
See a number that looks wrong?